Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter’s lead program, AMT-260, an advanced treatment for TLE.
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.
By merging with New Haven’s SPAC Thimble Point Acquisition Corp., Pear will be valued at $1.6 billion.
Global science and technology innovator Danaher Corporation is adding another company to its ever-growing global operation.
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
Brooklyn ImmunoTherapeutics and Novellus have been doing quite a bit of business together lately, including a licensing agreement and co-locating at a research and development center. Now, a potential acquisition can be added to the growing list.
The new study findings may pave the way for Bristol Myers Squibb to receive additional approval for Breyanzi in a vulnerable patient population.
This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.
Valo Health is the latest company to go public through a merger with a special purpose acquisition company. It will merge with Khosla Ventures Acquisition Co. and begin to trade on the Nasdaq.